Up­dat­ed: FDA ap­proves Pfiz­er’s he­mo­phil­ia B gene ther­a­py, with $3.5M price tag

Pfiz­er an­nounced Fri­day morn­ing that the FDA ap­proved its gene ther­a­py for the rare ge­net­ic bleed­ing dis­or­der he­mo­phil­ia B.

The one-time treat­ment, known gener­i­cal­ly as fi­danaco­gene ela­parvovec, is in­di­cat­ed for adults with mod­er­ate-to-se­vere he­mo­phil­ia B. The phar­ma com­pa­ny will mar­ket the gene ther­a­py as Be­qvez. The treat­ment was first ap­proved in Cana­da in Jan­u­ary.

It’s the sec­ond gene ther­a­py ap­proved for he­mo­phil­ia B, af­ter CSL re­ceived a reg­u­la­to­ry nod for Hem­genix in 2022. Pfiz­er said Fri­day that it would price its ther­a­py at $3.5 mil­lion, the same amount as Hem­genix.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER